Browse 97 Psoriasis Medical Studies Across 309 Cities
27 Phase 3 Trial · 1288 Psoriasis Clinics
What Are Psoriasis Clinical Trials?
Clinical trials aim to find new, more tolerable treatments for patients with Psoriasis.
Scientists believe the autoimmune system attacks healthy skin cells and causes affected skin to grow faster than healthy skin. Psoriasis results from a genetic predisposition to the disease and environmental factors.
Clinical trials involve developing and testing treatments for topical application to alleviate symptoms and oral or injectable medication to treat medical causes and prevent flare-ups or worsening of the condition.
Because Psoriasis is a visible condition, measuring the outcome of medical intervention is relatively straightforward. The preferred method to assess the severity of the condition is the Psoriasis Area and Severity Index (PASI). The PASI index grades redness, scaliness, and thickness of lesions in ratings of 1 – 4.
A baseline is established for a clinical trial to be viable, and the treatment should provide a 75% improvement on the initial PASI rating.
There are other ways to monitor the severity of the disease:
Each assessment considers BSA, the body surface area affected, and QOL, quality of life measurement.
Why Is Psoriasis Being Studied Through Clinical Trials?
As an autoimmune disease, Psoriasis results in skin cells growing faster than usual and creating lesions on the body. The lesions become thick and inflamed, resulting in itchy, scaly patches growing on the body. Symptoms range from mild to severe and, in extreme cases, have a debilitating effect.
There are 6 Psoriasis, Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis, and Erythrodermic Psoriasis. Each variant manifests on the skin and causes mild to severe discomfort.
What Are The Types of Treatments Available For Psoriasis?
Treatment for Psoriasis is divided into topical, oral, and injectables. Patients may use a combination of treatment types based on the most effective relief from symptoms and the spread of the disease.
What Are Some Recent Breakthrough Clinical Trials For Psoriasis?
2022: Sotyktu (Deucravacitinib) is one of the new-generation oral medications for Psoriasis and is FDA-approved. After a 112-week treatment regime, patients showed an 82.4% improvement, of which 52.5% reached a PASI rating of 90, indicating little to no symptoms.
2022: VTAMA (Tapinarof Cream) 1% is a non-steroidal cream used to treat mild to severe Psoriasis in adults. Patients using VTAMA showed, on average, a 75% improvement compared to their baseline symptoms. VTAMA is safe to use in all areas of the body.
Who Are Some Of The Key Opinion Leaders In Psoriasis Clinical Trial Research?
Mark G Lebwohl, MD Dermatology, Internal Medicine, is the Dean of Clinical Therapeutics at the Kimberly and Eric J Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. He has chaired many synopses on Psoriasis Research and written several books on the topic of Psoriasis.
Dr. Kim A Papp, MD, Ph.D., FRCPC, has 25 years of experience as a Principle Investigator and has conducted many trials in Psoriasis. He is a consultant to 40 pharmaceutical companies and the author of 800 publications.